trial

A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia

NCTId NCT06589817
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Not Yet Recruiting
Enrollment 376 (estimated)
Sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Primary completion 2026-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Not Yet Recruiting
Enrollment
376 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-10
Primary completion
2026-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Hydrochloride Carliprazine capsulesAripiprazole

Sponsors

Chengdu Kanghong Pharmaceutical Group Co., Ltd.Lead Sponsor

Sites

0 total

Linked catalysts

1
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in — primary completion2026-06

Facts & assertions

4 sourced
Enrollment
376
Phase
PHASE3
Primary Completion Date
2026-06
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Hydrochloride Carliprazine capsules
drug
Aripiprazole
drug
lead_sponsor
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
company
indication
Acute Schizophrenia
indication